目的 探討丹參注射液聯(lián)合替格瑞洛片治療急性心肌梗死的臨床療效。方法 選取宜興市人民醫(yī)院2020年2月—2023年8月收治的72例急性心肌梗死患者，按照隨機(jī)數(shù)字表法將所有患者分為對(duì)照組（36例）和治療組（36例）。對(duì)照組口服替格瑞洛片，1片/次，2次/d。治療組在對(duì)照組基礎(chǔ)上靜脈滴注丹參注射液，10 mL加入300 mL葡萄糖注射液，1次/d。所有患者持續(xù)治療2周。比較兩組的臨床療效、胸痛程度、心功能指標(biāo)和血清指標(biāo)。結(jié)果 治療組總有效率為94.44%，對(duì)照組總有效率為77.78%，組間差異顯著（P＜0.05）。治療后，兩組的胸痛發(fā)作頻率、發(fā)作持續(xù)時(shí)間均比治療前?。?i>P＜0.05），且治療組胸痛發(fā)作頻率、發(fā)作持續(xù)時(shí)間明顯比對(duì)照組?。?i>P＜0.05）。治療后，兩組的左室射血分?jǐn)?shù)（LVEF）、每搏輸出量（SV）、心臟排血指數(shù)（CI）均高于治療前（P＜0.05），且治療組LVEF、SV、CI比對(duì)照組高（P＜0.05）。治療后，兩組的載脂蛋白A（Apo-A）水平顯著升高，超敏肌鈣蛋白（hs-cTn）、脂蛋白相關(guān)磷脂酶A2（Lp-PLA2）水平顯著降低（P＜0.05）；治療組的Apo-A水平高于對(duì)照組，hs-cTn、Lp-PLA2水平低于對(duì)照組（P＜0.05）。結(jié)論 丹參注射液聯(lián)合替格瑞洛片治療急性心肌梗死的療效確切，可減輕胸痛程度，提高心功能，減輕心肌損傷。

Objective To investigate the clinical effect of Danshen Injection combined with Ticagrelor Tablets in treatment of acute myocardial infarction. Methods Patients (72 cases) with acute myocardial infarction in Yixing People's Hospital from February 2020 to August 2023 were divided into control and treatment groups according to the random number table method, and each group had 36 cases. Patients in the control group were po administered with Ticagrelor Tablets, 1 tablet/time, twice daily. Patients in the treatment group were iv administered with Danshen Injection on the basis of the control group, 10 mL added into 300 mL glucose injection, once daily. Patients in two groups were treated for 2 weeks. The clinical efficacies, the degree of chest pain, the cardiac function indicators, and the serum indicators in two groups were compared. Results The total effective rate of the treatment group was 94.44%, while the total effective rate of the control group was 77.78%, with a significant difference between the groups (P < 0.05). After treatment, the frequency and duration of chest pain attacks in both groups were lower than those before treatment (P < 0.05), and the indexes in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, LVEF, SV, and CI of two groups were higher than before treatment (P < 0.05), and the cardiac function indicators of the treatment group were higher than those of the control group (P < 0.05). After treatment, the levels of Apo-A in two groups significantly increased, while the levels of hs-cTn and Lp-PLA2 in two groups significantly decreased (P < 0.05). The levels of Apo-A in the treatment group was higher than that in the control group, while the levels of hs-cTn and Lp-PLA2 in the treatment group were lower than those in the control group (P < 0.05). Conclusion Danshen Injection combined with Ticagrelor Tablets can improve the efficacy of acute myocardial infarction, reduce the degree of chest pain, improve heart function, and alleviate myocardial damage.

R972

江蘇大學(xué)教育教學(xué)改革與研究課題（臨床醫(yī)學(xué)專(zhuān)項(xiàng)）（JLY2021220）